Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | President | November 19, 2020 | November 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date November 19, 2020 · Filed November 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2030-11-19 | Direct | 60,000 |
Reported balance
After 2020-11-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-11-19 · Grant · Acquired 60,000 · Balance 60,000 F1: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan in connection with the pricing of the Issuer's initial public offering. These options will vest 25% on November 19, 2021 and in equal monthly installments thereafter over the next three years, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan in connection with the pricing of the Issuer's initial public offering. These options will vest 25% on November 19, 2021 and in equal monthly installments thereafter over the next three years, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2020 Filed Nov 23, 2020 17:29 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031939 · doc4.xml · derivative · entry 1 Tardif Eric · CIK 0001453864 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Stock · 60,000 shares Expires 2030-11-19 F1 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan in connection with the pricing of the Issuer's initial public offering. These options will vest 25% on November 19, 2021 and in equal monthly installments thereafter over the next three years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.